Needham & Company Cuts Price Target on AtriCure (ATRC) to $20; Reiterates Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
AtriCure Reports Second Quarter 2016 Financial Results
August 4, 2016 4:01 PM EDTRevenue of $39.7 million up 21.8% as reported, 21.5% constant currency U.S. sales of $30.9 million up 19.9% International sales of $8.8 million up 28.7% as reported, 27.4% constant currency
MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2016 financial results.
We are pleased to report second quarter results which reflect many accomplishments we launched two new products, made progress with our clinical trials and made strides in... More
